Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5806493 | 0.85 | CYP3A4 (0.47) | ALDH1A1ALOX15TSHRTDP1L3MBTL1 | |
| SCHEMBL2832871 | 0.82 | CES2 (0.52) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL25574049 | 0.82 | ESR1 (0.45) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL28740020 | 0.79 | CES2 (0.48) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL6062757 | 0.79 | CES2 (0.62) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL3398637 | 0.79 | CES2 (0.62) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL8378855 | 0.79 | CES2 (0.62) | CES2CES1ALDH1A1ALOX15KMT2A | |
| SCHEMBL2359279 | 0.78 | ALDH1A1 (0.58) | ALDH1A1ALOX15TSHRTDP1MAPT | |
| SCHEMBL22734770 | 0.78 | CES2 (0.52) | CES2CES1KMT2AMEN1TDP1 | |
| SCHEMBL31711359 | 0.78 | NPC1 (0.49) | KMT2ATSHRMEN1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109438452-A | The method of level-one amine guiding building 6- (2- fluorophenyl) indoles simultaneously [1,2-a] quinoxaline | 桂林理工大学 | 2019-03-08 | — | — | CN | claimed |
| CN-108101856-A | Acyl group substitutes the preparation method of pyrazine compounds | 河南农业大学 | 2018-06-01 | — | — | CN | claimed |
| CN-113072440-A | Amphiphilic fluorine-containing benzoyl formate photoinitiator suitable for LED photopolymerization and preparation method thereof | 北京化工大学 | 2021-07-06 | — | — | CN | disclosed |
| US-20200385328-A1 | METHOD FOR PRODUCING BENZOYL FORMIC ACID COMPOUND AND PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| CN-108101856-B | Preparation method of acyl-substituted pyrazine compound | HENAN AGRICULTURAL UNIVERSITY (CN) | 2019-12-10 | — | — | CN | disclosed |
| CN-109438452-A | The method of level-one amine guiding building 6- (2- fluorophenyl) indoles simultaneously [1,2-a] quinoxaline | 桂林理工大学 | 2019-03-08 | — | — | CN | disclosed |
| CN-109438452-A | The method of level-one amine guiding building 6- (2- fluorophenyl) indoles simultaneously [1,2-a] quinoxaline | 桂林理工大学 | 2019-03-08 | — | — | CN | disclosed |
| CN-108101856-A | Acyl group substitutes the preparation method of pyrazine compounds | 河南农业大学 | 2018-06-01 | — | — | CN | disclosed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | disclosed |
| EP-0480918-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | disclosed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | disclosed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | disclosed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | disclosed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385328-A1 | METHOD FOR PRODUCING BENZOYL FORMIC ACID COMPOUND AND PYRIDAZINE COMPOUND | SDHA, FDPS, NDUFS5 | CES2 3534/4885CES1 4147/4885ALDH1A1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.